PTS Diagnostics and Blinded Diagnostics Collaborate on Clinical Trial

SADDLEBROOK, N.J. - May 15, 2015 - PRLog -- PTS Diagnostics, in partnership with Blinded Diagnostics, is providing encrypted point-of-care diagnostics and support services for an international phase III clinical trial. The trial is sponsored by a major global biopharmaceutical company in support of a new drug addressing lipidemia which impacts cardiometabolic diseases worldwide. The encrypted CardioChek Plus analyzer will be used throughout the clinical trial to monitor clinical decision points while providing increased efficiency in the form of improved timelines for both site investigators as well as participants.

The CardioChek Plus analyzer, which provides lipid panel and glucose results in as little as 90 seconds, uses clinical trial industry-standard encryption for patient’s results. Encrypted results are then electronically sent for off-site decryption. Neither the patient nor the clinician performing the fingerstick test knows the results.

“This point-of-care diagnostic technology will be utilized on two continents. As a component of the overall program,Blinded Diagnostics will train and provide support of all sites in the proper use and quality control of the devices for the trial,” said Steve Karuppan, CEO of Blinded Diagnostics. “This is just one example of how the partnership between PTS Diagnostics and Blinded Diagnostics can create efficiencies for pharmaceutical clinical development.”

This application of point-of-care technology will change the paradigm for clinical trials.

“This technology will provide much faster testing results to clinical trial’s contract service organizations,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We anticipate significant demand from the industry given our combined ability to quickly and accurately measure lipid results, securely encrypt measurements, send off-site and decrypt. This technological advance changes the landscape for clinical trials.”

PTS Diagnostics’ product lines also include handheld, highly-accurate, fast and economical diagnostic devices that empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care:

·         The CardioChek Plus analyzer addresses the connection between heart attack, stroke, and diabetes by providing simultaneous on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) and glucose screening results in as little as 90 seconds. The CardioChek Plus analyzer also calculates LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.

·         The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient.

About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 133 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim.

About Blinded Diagnostics

Blinded Diagnostics is a pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that provide same day lab test results for pharmaceutical clinical trials. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the forefront of a paradigm shift that brings flexibility and efficiency for trial sponsors. www.blindeddiagnostics.com

All trademarks used or mentioned in this release are protected by law.

For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at 317-870-5610.